-
Search Underway for 'Dooars Rani' Tigress After Second Escape from Buxa Tiger Reserve
-
Teatro Mayor Unveils 152-Performance 2027 Season Highlighting Beethoven and García Márquez
-
The Dilemma of Recording Live Music: Preserving Memories vs. Being Present
-
Rutgers Defeats NJIT 101-64 Behind Francis and Mark Scores
-
Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder
-
Healixa's FrostPulse(TM) Technology Solves a Major Roadblock to Data Center Growth: Cooling Without the Water Burden
-
Route1 Announces 2026 Annual Meeting Results
-
NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
-
Ethur Takes On Hiring Fraud With Facial Biometrics Identity Checks and Connected Payroll and Bank Data
-
PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
-
Green Leaf Innovations (OTC: GRLF) Meets OTCID Disclosure Requirements Following Profitable Q2 2026 Results
-
Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference
-
XCF Global Hosts USDA at New Rise Renewables Reno as Facility Surpasses 4.4 Million Gallons Since Restart
-
Amarc Extends 2026 Exploration Program at the Duke District: Initiates Drilling Program at Established Porphyry Copper-Gold Targets
-
AmeriLife Welcomes Finance Veteran Richard Dziadzio as Chief Financial Officer; Names Jim Quinn President & Chief Transformation Officer
-
Trifecta Gold Reports 2026 Exploration Results from the Liam and Lois Projects, Tombstone Gold Belt, Yukon
-
Irving Resources Reports on Drilling in Yamagano Mining Right at the Yamagano Joint Venture, Kyushu, Japan
-
NiobiumX Mining Reports Results of Ground Radiometric Survey at Shipshaw, Maps Two Distinct Radiometric Signatures Across the Core Claims, and Moves to a High-Resolution Airborne Survey of the Full 2,686-Hectare Package
-
BlackBerry to Participate in Upcoming Investor Conferences
-
Christmas Day Shifts More than Double as Americans Return to In-Person Holiday Celebrations
-
THIEAUDIO Introduces Clairvoyance MKII: The Evolution of a Signature Sound
-
Fulcrum Metals PLC Announces Publication of Updated Investor Presentation
-
Guardian Metal Resources PLC Announces Proposed Spin-Out of Non-Tungsten Projects
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 11
-
Fulcrum Metals PLC Announces New Critical Mineral Recoveries Expand Potential
-
6 Pieces of Furniture Worth Investing In
-
5E Advanced Materials to Host Fiscal First Quarter 2027 Earnings Conference Call on November 17, 2026
-
Sequoia Backs Microsoft Veterans' Edelbyte with $70M to Challenge Data Infrastructure Giants
-
Price Benowitz Earns 2027 Best Law Firm Recognition; 18 Attorneys Recognized by Best Lawyers
-
DaBella Honors More Than 200 Veteran Employees Nationwide This Veterans Day
-
ShelfieTech Announces Expansion Agreement for Its Next-Generation AI Retail Intelligence Platform
-
Resilient Energy Inc. (OTCID:RENI) Closes Acquisition of Mid River Midstream; Adds 12 Texas SWD Wells and $25M in Assets
-
SMX Expands Technology Portfolio With AI-Powered Scientific Intelligence Platform
-
LA Kush Cake Strain Guide Reviews Genetics and Historical Potency Data
-
Solid Aluminum, Deep Thock and 75% Compact Layout: Meet the Epomaker Galaxy75 Mechanical Keyboard
-
Who Is the Best Facial Feminization Surgeon?
-
CLS Health Advances Construction on New Webster Surgical Campus, Expanding Access to Care in Clear Lake Area
-
Cognitum One Launches Cognitum Spaces, the Governed System of Record for Physical Sites That Gives Enterprise AI Agents Trusted Real-World Context
-
OneMeta Provides Real-Time AI Translation for 2026 G20 Interfaith Forum Summit
-
Cosmos Health Provides U.S. E-Commerce Update for October 2026: Monthly Subscription Value Reaches $1.83 Million, Approximately $22 Million Annualized
-
LiveOne (Nasdaq: LVO) to Report Second Quarter Fiscal 2027 Financial Results on November 12, 2026
-
Arrive AI Announces Strategic Investment in Ottonomy to Accelerate Autonomous Delivery Network Expansion
-
Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
-
Healthcare Leaders Identify Priorities for Agentic AI Adoption in 2027-2028 - Black Book
-
TAMKO and Kansas City Chiefs Announce 2026 Operation Rooftop Recipient
-
Marketing Worldwide Corporation (OTC:MWWC) Announces 1-for-350 Reverse Stock Split Effective November 11, 2026
-
Patriot Software Adds Performance Reviews to Patriot HR
-
Thukukile Zuma Resigns from ANC Johannesburg Leadership Amid Disciplinary Dispute
-
Russia Orders 100,000 Kometa Modules to Counter Ukrainian Electronic Warfare
-
CM Mohan Yadav Meets Bohra Spiritual Leader to Discuss Simhastha 2028 and Development
US Justice Dept taking abortion pill fight to Supreme Court
The US Justice Department said Thursday that it will go to the Supreme Court to appeal restrictions imposed on a widely-used abortion pill in the latest round of an intensifying battle over reproductive rights.
The decision by President Joe Biden's administration came just hours after an appeals court rejected moves to ban mifepristone outright, but imposed a series of measures restricting access to the pill.
Mifepristone, which was approved by the Food and Drug Administration (FDA) in 2000 and accounts for more than half the abortions in the United States, has become the centerpiece of the country's latest clash over women's reproductive freedom.
Attorney General Merrick Garland said the Justice Department will be "seeking emergency relief from the Supreme Court to defend the FDA's scientific judgment and protect Americans' access to safe and effective reproductive care."
Speaking to reporters during Biden's visit to Dublin, Ireland, White House Press Secretary Karine Jean-Pierre said "we believe that the law is on our side, and we will prevail."
Late Wednesday, the US Fifth Circuit Court of Appeals said mifepristone, also known as RU 486, should remain available pending a full hearing of the case, but limited access to the first seven weeks of pregnancy, down from 10.
The appeals court also said in-person visits would be necessary to obtain the pill -- a requirement lifted in recent years -- and blocked the medication from being sent by mail.
The 2-1 ruling by the conservative-majority appeals court in New Orleans, Louisiana, came after a US District Court judge in Texas overturned the FDA's two-decades old approval of the drug last Friday.
- 'Furious' -
The appeals court said anti-abortion opponents had waited too long to challenge the drug's approval by the FDA but the judges' decision to impose restrictions on its use was denounced by groups seeking to maintain access to abortion.
"We are furious that yet another court would choose to jeopardize the health and futures of the millions of people who rely on mifepristone for abortion care," said Planned Parenthood president Alexis McGill Johnson.
Jennifer Dalven, director of the ACLU Reproductive Freedom Project, said "unless the Supreme Court steps in, this decision will prevent many people from getting abortion care and force them to remain pregnant against their will."
The anti-abortion group Susan B. Anthony described the appeals court ruling by two judges appointed by former Republican president Donald Trump as a "win."
"The court recognized that the abortion pill is dangerous and rolled back Biden's reckless mail-order abortion scheme," said Susan B. Anthony state policy director Katie Daniel. "We look forward to the Supreme Court hearing this case."
The latest standoff over abortion rights comes nearly a year after the Supreme Court, where conservatives wield a 6-3 majority, overturned the landmark Roe v. Wade ruling that had enshrined the constitutional right to abortion for half a century.
Mifepristone is one component of a two-drug regimen that can be used in the United States through the first 10 weeks of pregnancy.
It has a long safety record, and the FDA estimates 5.6 million Americans have used it to terminate pregnancies since it was approved.
- 'Unborn human' -
Last week's ruling by Judge Matthew Kacsmaryk, also a Trump appointee, seeking to impose a nationwide ban on mifepristone came in response to a suit by a coalition of anti-abortion groups.
The judge, in his decision, adopted language used by abortion opponents, saying the drug was used to "kill the unborn human."
Kacsmaryk said the two-drug regimen that includes mifepristone had resulted in "thousands of adverse events suffered by women and girls," including intense bleeding and psychological trauma.
But the FDA, researchers and the drugmaker say decades of experience have proven the medication to be safe and effective when used as indicated.
The Biden administration and leading pharmaceutical and biotech companies also argued that Kacsmaryk's ruling risked undermining the entire drug approval authority of the FDA.
"If this decision stands, no medication -- from chemotherapy drugs, to asthma medicine, to blood pressure pills, to insulin -- would be safe from attacks," said Vice President Kamala Harris.
Polls repeatedly show a clear majority of Americans support continued access to safe abortion, even as conservative groups push to limit access to the procedure -- or ban it outright.
A.Mahlangu--AMWN